As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.
Med Ad News talked to Bill Dreitlein – Senior Director, Pipeline & Drug Surveillance at OptumRx – about some of the most promising new molecular entities in the industry pipeline and challenges the FDA has faced during the COVID-19 pandemic.
Todd Wills, Managing Director, Consulting Services at CAS, talked to Med Ad News about what COVID-19 has taught us about pharmaceutical R&D; insights and predictions on future drug approval trends; and other topics.
The promise of personalized medicine, with its potential for treatments tailored to individual patients’ genomic footprints to generate better outcomes, has long tantalized the life sciences industry. Now, advanced imaging analytics and the extraction of high dimensional data from medical images, called radiomics, is emerging as the other side of the personalization coin.
Kevin Jacob, Head of Imaging at Illingworth Research Group (a SYNEOS HEALTH company), touches upon the myriad potential applications of medical photography and explore key considerations for use of these highly technical imaging techniques in clinical trials.
As pharma companies bolster their pipelines via multibillion-dollar acquisitions, drug manufacturers continue to heavily invest in the oncology space.
Oncology is one of the most exciting areas in healthcare, as novel therapies continue to emerge that move forward our molecular understanding of the disease and offer effective treatment advances. This Q&A explores oncology innovation with Kantar’s Stephanie Hawthorne, Vice President of Oncology and Specialty Therapeutics.
MedAdNews spoke to Bill Dreitlein, Senior Director, Pipeline & Drug Surveillance at OptumRx, about the state of the industry’s prescription drug pipeline and what enticing prospects will soon emerge.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.